Key facts
- This page summarizes Ted D. Kellner's Form 4 filing for AIM ImmunoTech Inc. (AIMI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 23 Apr 2025, 16:35.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Purchase
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
Shares purchased pursuant to a purchase agreement executed on April 11, 2025, but first required approval from the NYSE American which was received on April 21, 2025.
Footnote F2
Shares held by Kelvest I LP, for which the reporting person serves as Manager of T&M Partners LLC, General Partner of Kelvest I LP.
Footnote F3
Shares held by the Beta Fund Investment Club, for which the reporting person serves as the manager and is an investor. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Footnote F4
Shares held by the Kellner, Ted Combined Profit Sharing/Money Purchase Plan, for which the reporting person serves as trustee.
Footnote F5
Amends prior Form 3 filed by the reporting person with the SEC on 12/23/2024 due to a restructuring of family entities effective April 1, 2025. The reporting person is beneficial owner due to his role as Manager of T&M Partners LLC which serves as General Partner of a newly formed pooled investment vehicle that controls shares of the Company not previously reported on Form 3."